The DNTTIP1 Knockout NCI-H1975 Polyclonal Cells product offers a CRISPR/Cas9-edited polyclonal knockout population targeting the DNTTIP1 gene in the human NCI-H1975 lung adenocarcinoma cell line. This pooled knockout model provides a heterogeneous loss-of-function resource, generated by Cas9-mediated DNA cleavage within DNTTIP1, yielding a mixture of edited cells suitable for functional genomics studies where clonal variation is minimized. Researchers can employ this polyclonal knockout pool to investigate the role of DNTTIP1 in transcriptional regulation without the biases associated with monoclonal selection.
NCI-H1975 is an adherent epithelial cell line derived from a non-small cell lung cancer (NSCLC) patient and harbors the activating EGFR L858R mutation, making it a widely used model for EGFR-driven lung adenocarcinoma. This genetic background is critical for studying oncogenic signaling and therapeutic resistance mechanisms. The cells?? adherent morphology facilitates standard culture and assay protocols, enabling robust experimental reproducibility.
DNTTIP1 encodes a transcriptional corepressor that bridges transcription factors and histone deacetylase complexes. The protein physically interacts with terminal deoxynucleotidyltransferase (TdT) and recruits HDAC1 and HDAC2 to target loci, promoting histone deacetylation and chromatin condensation. DNTTIP1 is found in complexes with MLL/KMT2A components MEN1 and ASH2L, as well as the SIN3A corepressor. Upstream, DNTTIP1 expression is regulated by EGFR signaling through downstream effectors such as E2F1, MYC, and SP1. Downstream, DNTTIP1-mediated repression targets genes like CDKN1A and pro-apoptotic factors, linking its activity to cell cycle control and survival.
In NCI-H1975 cells, constitutive EGFR signaling may enhance DNTTIP1 activity, leading to sustained suppression of tumor suppressor genes. Consequently, CRISPR-mediated disruption of DNTTIP1 in this polyclonal population is expected to derepress these targets, potentially restoring CDKN1A expression and promoting apoptosis. This model is therefore particularly valuable for dissecting epigenetic contributions to EGFR-mutant lung adenocarcinoma maintenance and for examining cross-talk between corepressor complexes and oncogenic kinases. Moreover, DNTTIP1 loss may sensitize cells to HDAC inhibitors, offering a platform for combination therapy studies.
This knockout product is well-suited for a range of advanced assays, including ChIP-qPCR to assess histone H3 acetylation changes at DNTTIP1 target promoters, Western blotting for HDAC1/2 complex integrity, and RT-qPCR profiling of downstream gene expression. Cell-based functional assays such as MTT viability, colony formation, and caspase-3/7 apoptosis measurements enable phenotypic characterization. Additionally, drug sensitivity testing with HDAC inhibitors and RNA-seq for transcriptome-wide analysis can yield mechanistic insights. Researchers can also employ wound-healing migration assays to explore DNTTIP1??s role in tumor cell motility. For further inquiries, please contact Ascent Research.
